Stockscreener 앱 받기
105.81
0.02%
0.02
시간 외 거래:
103.88
-1.93
-1.82%
전일 마감가:
$105.79
열려 있는:
$106.95
하루 거래량:
1.18M
Relative Volume:
1.44
시가총액:
$6.45B
수익:
$521.31M
순이익/손실:
$-23.36M
주가수익비율:
-221.31
EPS:
-0.4781
순현금흐름:
$54.87M
1주 성능:
+12.56%
1개월 성능:
+12.36%
6개월 성능:
+50.96%
1년 성능:
+139.66%
1일 변동 폭
$105.51
$110.11
1주일 범위
$88.34
$110.48
52주 변동 폭
$40.00
$110.48
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
105.81 | 6.45B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
How The Mirum Pharmaceuticals (MIRM) Story Is Evolving With New Analyst Targets And Trial Milestones - Yahoo Finance
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets - Sahm
Mirum Pharmaceuticals rally reflects confidence in late-stage liver disease assets - MSN
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals stock hits all-time high at 109.29 USD By Investing.com - Investing.com Australia
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach - TechStock²
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
MIRM Stock Jumps As HDV Data Fuel Bullish Targets - timothysykes.com
Mirum Pharmaceuticals stock surges 12% on trial results By Investing.com - Investing.com Canada
Mirum Pharma - TradingView
MIRM: Volixibat met its primary endpoint in PSC, showing robust itch reduction and strong safety - TradingView
Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo - Yahoo Finance
MIRM Stock Jumps As HDV Data Sends Analysts Scrambling Higher - StocksToTrade
Up to BAT in PSC, Mirum base case proven with phase IIb - BioWorld News
Mirum Pharmaceuticals stock hits all-time high at 109.29 USD - Investing.com
Mirum Pharmaceuticals Reports Positive Volixibat Phase 3 Results for Cholestatic Pruritus in PSC – Efficacy and Safety Data Released - Minichart
Mirum’s volixibat meets primary endpoint in PSC pruritus trial - Investing.com UK
Baird reiterates Mirum Pharmaceuticals stock rating on positive trial data By Investing.com - Investing.com Canada
MIRM: Volixibat met its Phase 2b endpoint, significantly reducing pruritus in PSC patients - TradingView
MIRM: Volixibat significantly reduced pruritus in PSC patients, meeting the VISTAS Phase 2b primary endpoint - TradingView
MIRM: Volixibat and brelovitug achieved key efficacy and safety milestones in PSC and HDV Phase 2b trials - TradingView
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial - TipRanks
Mirum’s volixibat meets primary endpoint in PSC pruritus trial By Investing.com - Investing.com Canada
Mirum Pharmaceuticals' Volixibat Meets Primary Endpoint in VISTAS Phase 2b for PSC Itch - TradingView
Volixibat eases cholestatic itch in PSC trial for Mirum (NASDAQ: MIRM) - Stock Titan
Mirum Pharmaceuticals Announces Primary Endpoint Met In VISTAS Study Of Volixibat In Patients With Primary Sclerosing Cholangitis - marketscreener.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Resu - The National Law Review
Mirum Pharmaceuticals to Announce Volixibat Primary Sclerosing Cholangitis VISTAS Study Results on May 4, 2026 - geneonline.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 | FinancialContent - FinancialContent
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Earnings Preview: MIRM to Report Financial Results Post-market on May 06 - Moomoo
Pictet Asset Management Holding SA Purchases 35,997 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - BioSpace
Mirum Pharmaceuticals, Inc. (MIRM) expected to beat earnings estimates: What to know ahead of Q1 release - MSN
All eyes on Mirum Pharmaceuticals earnings ahead of PSC trial data - Investing.com Australia
All eyes on Mirum Pharmaceuticals earnings ahead of PSC trial data By Investing.com - Investing.com India
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada
Stifel Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $130 - Moomoo
HC Wainwright Has Pessimistic Outlook of MIRM Q1 Earnings - MarketBeat
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum HDV Trial Success Adds New Late Stage Growth Option - Yahoo Finance
Stifel raises Mirum Pharmaceuticals price target on pipeline outlook By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $112.00 at Robert W. Baird - MarketBeat
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - BioSpace
Mirum’s hepatitis delta drug meets phase 2b study goals - Investing.com UK
BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):